Supplementary Table 1: TPF dose and schedule in various Phase III studies in head and neck cancer.
|
Study |
Induction chemotherapy regimen |
Concurrent chemotherapy |
|
TAX 323 [7] |
Docetaxel 75 mg/m2 D1 Cisplatin 75 mg/m2 D1 5FU 750mg/m2 D1-5 Q3 weeks |
Nil |
|
TAX 324 [8, 9] |
Docetaxel 75 mg/m2 D1 Cisplatin 100 mg/m2 D1 5FU 1000mg/m2 D1-4 Q3 weeks |
Carboplatin AUC x 1.5 Q1 week |
|
GORTEC 2000-01 [27] |
Docetaxel 75 mg/m2 D1 Cisplatin 75 mg/m2 D1 5FU 750mg/m2 D1-5 Q3 weeks |
Cisplatin, carboplatin, and 5-fluorouracil or a combination of two drugs *
|
|
TTCC 2002 [30] |
Docetaxel 75 mg/m2 D1 Cisplatin 75 mg/m2 D1 5FU 1000mg/m2 D1-5 Q3 weeks |
Cisplatin 100 mg/m2 Q3 weeks |
|
DeCIDE [31] |
Docetaxel 75 mg/m2 D1 Cisplatin 75 mg/m2 D1 5FU 750 mg/m2 D1-5 Q3 weeks |
Hydroxyurea at 500 mg PO q12 hours × 6 days, 5-FU at 600 mg/m2/day × 5 days, Docetaxel D1 starting at 20 mg/m2 (increasing by 5 mg/m2 in successive dose levels, maximum 30 mg/m2) Q2W |
|
PARADIGM [32] |
Docetaxel 75 mg/m2 D1 Cisplatin 100 mg/m2 D1 5FU 1000 mg/m2 D1-4 Q3 weeks |
Weekly carboplatin AUC x 1.5 or Weekly docetaxel 20 mg/m² for 4 weeks (poor responder only) |
|
Italian trial [33] |
Docetaxel 75 mg/m2 D1 Cisplatin 80 mg/m2 D1 5FU 800 mg/m2 D1-4 Q3 weeks |
Cisplatin 20 mg/m2 D1-4 and 5FU 800 mg/m2 D1-D4 (weeks 1 and 6) or weekly cetuximab 250 mg/m2 |
AUC: Area Under the Concentration-Time-Curve. *Details (scheme and dosage) not stated.